IP Library › Granted Patent US 12,472,263
Granted Patent B2
US 12,472,263 · App. 16/977,973 · Granted Nov 18, 2025

Ophthalmic formulation

Inventors: Stefan Sperl (Vienna, AT); Franz Obermayr (Vienna, AT)
Assignee: PANOPTES PHARMA GES.M.B.H
A61K47/643A61K9/0048A61K9/06A61K31/381A61P27/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,472,263
App. No.
16/977,973
Granted
Nov 18, 2025
Kind
B2
Abstract

The present invention provides an ophthalmic composition comprising an active pharmaceutically compound non-covalently bound to albumin. The composition of the present invention is useful for treatment of ophthalmic diseases and disorders.

Claims (12)

1 . An ophthalmic composition comprising 3-(2,3,5,6-tetrafluoro-3′trifluoromethoxy-biphenyl-4-ylcarbamoyl)-thiophene-2-carboxylic acid (PP-001) as an ophthalmic pharmaceutically active compound and albumin, wherein the ophthalmic composition is in the form of an eye drop.

2 . The ophthalmic composition of claim 1 , wherein said albumin is human serum albumin, recombinant human serum albumin, serum albumin that has at least a one amino acid truncation at its N-terminal end, or prealbumin.

3 . The ophthalmic composition of claim 1 , further comprising one or more pharmaceutically acceptable excipients and/or carriers.

4 . The ophthalmic composition of claim 1 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of surfactants, preservatives, viscosity regulators, pH-adjusting agents, stabilizers, and tonicity-regulators.

5 . The ophthalmic composition of claim 1 , wherein the pharmaceutically active compound is comprised from about 0.005% to about 20% by weight.

6 . The ophthalmic composition of claim 1 , wherein albumin is comprised from about 1% to about 30% by weight.

7 . The ophthalmic composition of claim 1 , wherein the weight ratio of albumin to the pharmaceutically active compound in the ophthalmic composition is about 1:5, or 1:1, or 20:1, or 400:1, or more.

8 . The ophthalmic composition of claim 1 , wherein the ophthalmic composition is for topical ocular instillation.

9 . A method for treatment of a patient suffering from dry eye syndrome, post-cataract surgery, glaucoma, conjunctivitis, allergy, bacterial infection, blepharitis, infectious corneal ulcers, corneal abrasions, ocular inflammation, corneal transplants, or uveitis, comprising administering to the patient the ophthalmic composition of claim 1 .

10 . The method of claim 9 , wherein the dry eye syndrome is aqueous tear-deficient dry eye or evaporative dry eye.

11 . The method of claim 9 , wherein the dry eye syndrome eye is selected from the group consisting of alacrima, xerophthalmia, Sjogren syndrome, dry keratoconjunctivitis, Stevens-Johnson syndrome, ocular pemphigoid, dry eye after ophthalmic operation, dry eye accompanied with allergic conjunctivitis, dry eye like conditions including tear decrement of VDT (Visual Display Terminal) worker and tear decrement without any systemic symptom caused by dry room due to air conditioning.

12 . The ophthalmic composition of claim 2 , wherein said albumin is human serum albumin.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2020
From: SPERL, STEFAN; OBERMAYR, FRANZ
To: PANOPTES PHARMA GES.M.B.H
Reel/Frame 054763/0081 →
Priority Claims (1)
EP 18160981 · Mar 9, 2018 · regional
Continuity (1)
Related Publication 20210052737A1 · Feb 25, 2021
References Cited (65)
US 6743826B1 · Hegedus et al. · 2004 [cited by applicant]
US 7365094B2 · Leban et al. · 2008 [cited by applicant]
US 7714132B2 · Fecher et al. · 2010 [cited by applicant]
US 8354433B2 · Vitt et al. · 2013 [cited by applicant]
US 9795590B2 · Strobl · 2017 [cited by applicant]
US 11730716B2 · Sperl et al. · 2023 [cited by applicant]
US 12209073B2 · Sperl et al. · 2025 [cited by applicant]
US 20040176458A1 · Leban et al. · 2004 [cited by applicant]
US 20040192758A1 · Leban et al. · 2004 [cited by applicant]
US 20040254154A1 · Ashton · 2004 [cited by applicant]
US 20100280081A1 · Vitt et al. · 2010 [cited by applicant]
US 20110021465A1 · Minatelli et al. · 2011 [cited by applicant]
US 20110275603A1 · Muthuppalaniappan et al. · 2011 [cited by applicant]
US 20190025313A1 · Si et al. · 2019 [cited by applicant]
US 20230278979A1 · Sperl et al. · 2023 [cited by applicant]
US 20230285355A1 · Sperl et al. · 2023 [cited by applicant]
EP 0179477A2 · 1986 [cited by applicant]
EP 0413329 · 1991 [cited by applicant]
JP 0834320A1 · 1998 [cited by examiner]
JP 2006089485 · 2006 [cited by applicant]
JP 2009270356A · 2009 [cited by applicant]
WO 99013914A1 · 1999 [cited by applicant]
WO WO2003006425 · 2003 [cited by applicant]
WO 2004056747A1 · 2004 [cited by applicant]
WO 2004056797A1 · 2004 [cited by applicant]
WO WO2004056746 · 2004 [cited by applicant]
WO WO2006022442 · 2006 [cited by applicant]
WO WO2007038687 · 2007 [cited by applicant]
WO WO2008077639 · 2008 [cited by applicant]
WO WO2009021696 · 2009 [cited by applicant]
WO WO2010128050 · 2010 [cited by applicant]
WO WO2011138665 · 2011 [cited by applicant]
WO WO2015154820 · 2015 [cited by applicant]
WO 2015169944A1 · 2015 [cited by applicant]
WO WO2022214691 · 2022 [cited by applicant]
Shimmura et al., Albumin as a tear supplement in the treatment of sever dry eye, Br. J Ophthalmology 2003, 87: 1279-128 (Year: 2003). [cited by examiner]
Schuerer et al., “Ocular toxicity and ocular tissue distribution of topically applied PP-001 in vivo,” Abstract from the Annual Meeting of the Association for Research in Vision and Ophthalmology, Baltimore MD, May 7-11… [cited by applicant]
International Search Report and Written Opinion in PCT/EP2019/055818 issued May 29, 2019. [cited by applicant]
Yamasaki et al., Albumin-drug interaction and its clinical implication, Biochim Biophys Acta (BBA), 2013, 1830(12):5435-5443. [cited by applicant]
Berge et al., Jan. 1977, Pharmaceutical Salts, J. Pharm. Sci., 66(1):1-19. [cited by applicant]
Brittain, Dec. 1, 2009, Developing an appropriate salt form for an active pharmaceutical ingredient, American Pharmaceutical Review, 12(7):62-65. [cited by applicant]
CAS Registry No. 717142-73-9. Accessed Dec. 4, 2023, 2 pp. [cited by applicant]
Castiblanco et al., 2014, Review of systemic immunosuppression for autoimmune uveitis, Ophthalmol Ther, 3:17-36. [cited by applicant]
Chong et al., 2006, Concurrent Antiviral and Immunosuppresive Activities of Leflunomide In Vivo, Am. J. Transplant, 5(1):69-75. [cited by applicant]
Diedrichs-Mohring et al., 2018, Intraocular DHODH-inhibitor PP-001 suppresses relapsing experimental uveitis and cytokine production of human lymphocytes, but not of RPE cells J. of Neuroinflammation, 15(54):1-11. [cited by applicant]
European Agency for the Evaluation of Medicinal Products, Jan. 25, 2001, Note for Guidance on Plasma-Derived Medicinal Products, CPMP/BWP/265/95 rev. 3. [cited by applicant]
Fang et al., Apr. 2013, Amelioration of Experimental Autoimmune Uveitis by Leflunomide in Lewis Rats, PLoS ONE 8(4):e62071. [cited by applicant]
Hamrah et al., Apr. 2014, Impact of Corneal Pain on Quality of Life (QoL): The Ocular Pain Assessment Survey (OPAS) Study, ARVO Annual Meeting Abstract. [cited by applicant]
Kindsmuller et al., Sep. 2009, A 49-Kilodalton Isoform of the Adenovirus Type 5 Early Revion 1B 55-Kilodalton Protein Is Sufficient To Support Virus Replication, J. Viral. 83(18):9045-9056. [cited by applicant]
Klein, 2010, The use of biorelevant dissolution media to forecast the in vivo performance of a drug, The AAPS Journal, 12(3):397-406. [cited by applicant]
Kompella at el., 2011, Drug Product Development for the Back of the Eye, Springer, New York (TOC). [cited by applicant]
Marschall et al., 2012, In Vitro Evaluation of the Activies of the Novel Anticytomegalovirus Compound AIC246 letermovir) against Herpesviruses and other Human Pathogenic Viruses, Antimicrob. Agents Chemother. 56:1135-11… [cited by applicant]
Marschall et al., 2013, Assessment of drug candidates for broad-spectrum antiviral therapy targeting cellular pyrimidine biosynthesis, Antiviral Research, 100(3):640-648 with supporting information. [cited by applicant]
Meister, 2005, Antiviral Mechanism(s) of the Experimental Immunosuppressive Agent Leflunomide Against Human Cytomegalovirus and Polyomavirus, doctoral dissertation, Ohio State University, 141 pp. [cited by applicant]
Qazi, et al. Jul. 2016, Validity and Reliability of a Novel Ocular Pain Assessment Survey in Quantification and Monitoring of Corneal and Ocular Surface Pain, Ophthalmology, 123(7), 1458-1468. [cited by applicant]
Peyman et al., 2009, Intravitreal injection of therapeutic agents, retrieved from internet: https://insights.ovid.com/pubmed?pmid=19584648, 1 p. [cited by applicant]
Suhler et al., Jul. 2018, Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III, Ophthalmology, 125(7):1075-1087. [cited by applicant]
Baumgartner et al., 2006, Dual Binding Mode of a Novel Series of DHODH Inhibitors Journal of Medicinal Chemistry, 49(4):1239-1247. [cited by applicant]
Davis et al., 1996, The Immunosuppressive Metabolite of Leflunomide is a Potent Inhibitor of Human Dihydroorotate Dehydrogenase, Biochemistry, 35(4):1270-1273. [cited by applicant]
Leban et al., 2006, Biphenyl-4-ylcarbamoyl thiophene carboxylic acids as potent DHODH inhibitors, Bioorg Med Chem cell., 16(2):267-270. [cited by applicant]
Ozdemir et al., Jun. 14, 2022, Patient Medication Preferences for Managing Dry Eye Disease: the Importance of Medication Side Effects, Patient, 15:679-690. [cited by applicant]
Rechter et al., 2006, Antiviral activity of Arthrospira-derived spirulan-like substances, Antiviral Res. 72:197-206. [cited by applicant]
Sung et al., 1999, Intravitreal controlled release implant for leflunomide: Potential treatment for uveitis, Proceedings of he International Symposium on Controlled Release of Bioactive Materials, 26:38-39. [cited by applicant]
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Dec. 14, 2020, Dry Eye: Developing Drugs for Treatment Guidance for Industry, Draft Guidance. [cited by applicant]
Yeh et al., 2019, Suprachoroidal injection of triamcinolone acetonide, CLS-TA, for macular edema due to noninfectious uveitis, Retina 39(10):1880-1888. [cited by applicant]